Roche: positive phase II data in hypertension
The KARDIA-2 study not only met its primary endpoint, but also demonstrated an encouraging safety and tolerability profile for zilebesiran in adults with mild-to-moderate uncontrolled hypertension.
The results of the study will be presented in April at the annual meeting of the American College of Cardiology. Another Phase II study, KARDIA-3, has also been initiated in adults with uncontrolled hypertension at high cardiovascular risk.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction